Virtual Library
Start Your Search
P.E. Wuyung
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-026 - Circulating miR-206 in Advanced Stage Lung Cancer Patients and Its Association with Cancer Cachexia (ID 8061)
09:30 - 09:30 | Author(s): P.E. Wuyung
- Abstract
Background:
Cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients.
Method:
A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Subjects were patients with advanced lung cancers. Cachexia was defined as body mass index less than 20 kg/m[2] calculated after treatment. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. Blood from health subjects were also taken for comparison. The results were expressed as cycle threshold (C~T~) and fold change (FC) which was calculated using the 2[-ΔΔC]~T~ method.
Result:
Thirty-seven patients were enrolled; 27 (73.0%) were men. Patients’ mean age was 51.7+11.1 years. Most of the patients (91.9%) were in stage IV. There were 16 (43.2%) patients with cachexia after treatment. Compared to normal healthy subjects, circulating miR-206 expression level was 13.7 times higher in lung cancer patients (FC=13.699). Among cancer patients, miR-206 expression was slightly up-regulated in cachectic than non-cachectic patients (FC=1.355).
Conclusion:
Circulating miR-206 is overexpressed in advanced stage lung cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.
